Michael Anthony Bretherton is a British businessperson who has been at the head of 6 different companies. Currently, he is Non-Executive Chairman at Adams Plc, Chief Executive Officer & Executive Director at Sarossa Plc, Chief Financial Officer & Director at e-Therapeutics Plc and Non-Executive Chairman at Hardy Plc.
He is also on the board of Blake Holdings Ltd., ORA Capital Ltd. and Blake Holdings Ltd. (Jersey) and Member of Institute of Chartered Accountants in England & Wales.
In the past Michael Anthony Bretherton held the position of Independent Non-Executive Director at DeepMatter Group Plc, Director-Financial Operations at Mapeley Estates Ltd., Finance Director of ORA Capital Partners Ltd., Secretary & Non-Executive Director of DeepMatter Group Plc, Manager-Corporate Finance at The Plessey Co. Plc, Non-Executive Director at Nanoco Group Plc and Director at Nanoco Technologies Ltd. (a subsidiary of Nanoco Group Plc), Director & Finance Director at Woodbois Ltd., Executive Director & Finance Director for Abaco Capital Plc, Non-Executive Director at Tissue Regenix Group Plc Executive Chairman at Oxeco Plc and Director & Partner at Oxray Ltd. (both are subsidiaries of Tissue Regenix Group Plc), Director & Partner at Abway Enterprises Corp., Director & Partner at Ora Capital Services Ltd., Executive Chairman & Finance Director at Sarossa Capital Ltd., Finance Director for Bridgend Group Plc and Manager & Accountant at PricewaterhouseCoopers LLP (United Kingdom).
Michael Anthony Bretherton received an undergraduate degree from the University of Leeds.